The FDA has approved retifanlimab-dlwr, both alone and in combination with chemotherapy, for certain patients with anal squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved retifanlimab-dlwr (Zynyz) for patients with...
The FDA has approved telisotuzumab vedotin-tllv for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult...
The FDA has approved belzutifan for certain patients with pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg) for the treatment of patients 12 years and older with locally...
The FDA has approved avutometinib and defactinib for certain patients with KRAS-mutated low-grade serous ovarian cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to avutometinib and defactinib (Avmapki Fakzynja Co-pack)...
The FDA has approved penpulimab-kcqx for certain patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has approved penpulimab-kcqx in combination with chemotherapy for the first-line treatment of patients with nonkeratinizing nasopharyngeal carcinoma...
The FDA has approved nivolumab with ipilimumab as a first-line treatment for advanced liver cancer. The U.S. Food and Drug Administration (FDA) has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the...
The FDA has approved nivolumab with ipilimumab in certain patients with advanced colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the treatment of patients 12...
The FDA has approved the Immunotherapy durvalumab in combination with chemotherapy for certain patients with resectable bladder cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with chemotherapy before...
The FDA has approved the radiotherapy lutetium Lu 177 vipivotide tetraxetan for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for...
The FDA has approved the multi-kinase inhibitor cabozantinib for certain adult and pediatric patients with rare neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for patients 12 years and...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More